-transparent.png){kind=logo}
The results of controlled clinical trial that used high doses of medroxyprogesterone acetate (MPA) in the treatment of metastatic breast cancer are reported. Two treatment reigmens were used: regimen A, 500 mg daily with a total dose of 30 g; regimen B, 1,000 mg daily with a total dose of 60 g. The overall response rates were similar, with no statistically significant difference between the two treated groups. Regimen A (lower dosage group) reached a remission rate of 44%, whereas regimen B (higher dosage group) had a remission rate of 41%. The mean duration of response was 8 months with regimen A and 9 months with regimen B. The advantages of the lower dosage regimen as opposed to the higher dosage regimen of MPA in the treatment of advanced breast cancer are discussed.
G R Cuna, and
A Calciati, and
M R Strada, and
C Bumma, and
L Campio
November 1982,
Gan to kagaku ryoho. Cancer & chemotherapy,
G R Cuna, and
A Calciati, and
M R Strada, and
C Bumma, and
L Campio
October 1979,
Tumori,
G R Cuna, and
A Calciati, and
M R Strada, and
C Bumma, and
L Campio
January 1985,
Oncology,
G R Cuna, and
A Calciati, and
M R Strada, and
C Bumma, and
L Campio
February 1988,
Chemioterapia : international journal of the Mediterranean Society of Chemotherapy,
G R Cuna, and
A Calciati, and
M R Strada, and
C Bumma, and
L Campio
September 1984,
British journal of cancer,
G R Cuna, and
A Calciati, and
M R Strada, and
C Bumma, and
L Campio
January 1984,
Cancer immunology, immunotherapy : CII,
G R Cuna, and
A Calciati, and
M R Strada, and
C Bumma, and
L Campio
January 1996,
Srpski arhiv za celokupno lekarstvo,
G R Cuna, and
A Calciati, and
M R Strada, and
C Bumma, and
L Campio
January 1982,
Cancer chemotherapy and pharmacology,
G R Cuna, and
A Calciati, and
M R Strada, and
C Bumma, and
L Campio
August 1987,
Gan to kagaku ryoho. Cancer & chemotherapy,
G R Cuna, and
A Calciati, and
M R Strada, and
C Bumma, and
L Campio
February 1982,
Cancer treatment reports,
